IL17A and psoriasis: Therapeutic antibodies for blocking IL-17A have been developed for psoriasis and ankylosing spondylitis and one trial was registered combining secukinumab (anti-IL17) with camrelizumab (anti-PD1) therapy, but the current trial status is still unknown [86].